Prevail Therapeutics

Join us in celebrating #WomensEqualityDay! Today, we honor the 19th Amendment, passed in 1920, which granted women the right to vote. 💪   While we've made significant strides toward gender equality, there's still important work to be done, particularly in research and healthcare. Despite progress in education, women still represent fewer than 30% of researchers worldwide, highlighting a major disparity in science.   In honor of Women’s Equality Day, we’re shining a spotlight on an editorial in Frontiers in Neuroscience that showcases the groundbreaking contributions of women in neurodegenerative research. Their work is transforming our understanding of sex-specific effects in neurodegeneration, developing innovative cognitive assessment tools, and revealing the critical roles of glial cells in disease pathology.   As we continue to advocate for gender equality in healthcare research, let's ensure that every voice is heard and valued. Together, we can drive innovation and improve outcomes for all.   Read the full editorial here: https://lnkd.in/egS3FNpj #HealthcareEquality #WomenInScience #EqualityInHealthcare #WomenEmpowerment

At Prevail Therapeutics we're looking forward to the 14th International Conference on Frontotemporal Dementias taking place from September 19-22 in Amsterdam, the Netherlands. This biennial congress of the International Society of Frontotemporal Dementia (ISFTD) is a vital gathering for neurologists, psychiatrists, geriatricians, neuropsychologists, and basic scientists in frontotemporal dementia (FTD) and related neurodegenerative conditions. FTD caregivers are also encouraged to attend the caregiver’s program. FTD is the second most common cause of early-onset dementia, characterized by behavioral changes, language and motor disorders, and memory disorders. This conference will highlight the latest advancements in understanding the molecular basis of FTD and developing therapeutic approaches. Join us for a diverse program featuring keynote speeches, panel discussions, poster presentations, and networking opportunities. The conference also includes a caregiver's program and exhibits by industry and non-profit partners. Register today to be part of this enriching event. For more information and to register, visit: https://bit.ly/3WKDwFP #ISFTD2024 #FTD #DementiaResearch #Neurology #AlzheimerCenterAmsterdam #PrevailTherapeutics #HealthcareInnovation #PatientSupport

Prevail Therapeutics is excited to spotlight the National Society of Genetic Counselors (NSGC) and their invaluable contributions to the genetic counseling profession. Since its inception in 1979, the NSGC has advanced the roles of genetic counselors in healthcare by providing a robust network for professional communication, continuing education opportunities, and public policy advocacy. Genetic testing analyzes a person's DNA to identify changes or mutations in their genes or chromosomes. It can confirm or rule out a diagnosis, predict the risk of developing certain genetic conditions, and inform treatment decisions. Genetic counselors, who receive specialized training in medical genetics and counseling, play a crucial role in evaluating genetic risks and supporting patients in understanding their genetic test results and hereditary conditions. Genetic counselors are vital members of healthcare teams, offering expertise in various specialties such as prenatal, pediatric, oncology, neurology, and more. They also work in diverse roles beyond patient care, including research, education, and industry, contributing significantly to advancements in genetic science. Join us in recognizing the incredible work of the NSGC and the genetic counselors who empower patients with knowledge and support for their healthcare decisions. Learn more about the NSGC: https://bit.ly/3M0P16P #GeneticCounseling #HealthcareInnovation #NSGC #PrevailTherapeutics #Genetics #PatientSupport #HealthcareHeroes

We are excited to announce the upcoming Gaucher Community Alliance 2024 Patient & Family Conference. This event is a fantastic opportunity for patients, families, and the Gaucher community to come together, share experiences, and gain valuable insights. Prevail Therapeutics is proud to sponsor and attend this important event. Our commitment to advancing research and support for Gaucher disease remains strong, and we look forward to connecting with the Gaucher community. The conference will run from Sunday, September 15 to Tuesday, September 17 in Pittsburgh, PA.    Register now and join us for 3 days of education, support, and community building! https://bit.ly/46B7ssg #GCA2024 #GaucherDisease #PatientSupport #CommunityAlliance #PatientConference #GaucherCommunity #RareDisease

The Parkinson’s that people don’t see or don’t want to see. The Parkinson’s Foundation is hosting a webinar, as part of their Wellness Wednesday series which will focus on the less talked-about challenges associated with Parkinson’s disease. This session will discuss how these challenges impact individuals with Parkinson’s and provide guidance on how to talk to family and friends about the visible symptoms that can cause self-consciousness in social situations. Speaker: Taylor Rush, Health Psychologist, Cleveland Clinic Date: August 14, 2024 Time: 13:00–14:00 EST Location: Virtual (Zoom) This event is free, but registration is required. Register here: https://bit.ly/3YAcmDT It’s time to start talking openly about the daily challenges to improve quality of life and foster understanding. Parkinson's Foundation #ParkinsonsDisease #Together4PD #WellnessWednesday #OpenUp #PrevailTherapeutics #FreeEvent

Prevail Therapeutics would like to spotlight the incredible work of the Gaucher Community Alliance (GCA). The GCA, an independent nonprofit, is dedicated to serving patients with Gaucher disease and their families. Their mission is to provide peer-to-peer support, education, advocacy, patient and family resources, and networking. By fostering collaboration and emotional support, the GCA aims to alleviate some of the burdens associated with this rare disorder. The GCA’s vision is to ensure that no family faces Gaucher disease alone. They work tirelessly to educate, support, and advocate for the Gaucher community, helping patients and families live their fullest lives. Through their unwavering commitment, they provide vital educational programming, patient services, governmental and legislative advocacy, and collaborate with medical professionals to ensure comprehensive care. We are proud to recognize and support such a remarkable organization that makes a significant impact in the Gaucher community. To learn more about the GCA and how you can support their mission, visit: https://bit.ly/4chYbGI Gaucher Community Alliance #GaucherDisease #PatientSupport #HealthcareHeroes #GaucherCommunity #EmpowerPatients #RareDisease

Prevail Therapeutics is dedicated to pioneering innovative treatments that provide hope for individuals living with #FrontotemporalDementia with GRN mutations (FTD-GRN). Our PROCLAIM trial is a Phase 1/2 clinical trial investigating a potentially disease-modifying, single-dose gene therapy designed to elevate progranulin levels for individuals living with FTD-GRN. FTD-GRN is a rapidly progressing neurodegenerative disease caused by a lack of progranulin, a protein that is found both outside of brain cells and inside the cells, in the lysosomes. Healthy levels of progranulin are necessary for fundamental cellular processes, including lysosomal function and neuronal survival. In patients with FTD-GRN, mutations in the gene GRN cause the body to produce insufficient progranulin. Without enough of the enzyme, the lysosomes cannot effectively degrade or recycle proteins, leading to inflammation and neurodegeneration. The PROCLAIM trial is actively recruiting patients with FTD-GRN , aged 30–85 years. To learn more about PROCLAIM, visit our website: https://bit.ly/3WOrBrL #PROCLAIMTrial #GeneTherapy #FTD #NeurodegenerativeDisease #ClinicalTrials #AFTD

Prevail Therapeutics is pleased to announce a significant milestone in our Phase 1/2 PROPEL clinical trial for Parkinson’s disease with GBA1 mutations (PD-GBA): Cohort 1 is fully recruited, and we have now initiated enrollment of the 2nd cohort! This marks an exciting step in our journey to find effective treatments for PD-GBA. We extend our deepest gratitude to the dedicated clinical research teams, patient advocacy groups, and, most importantly, the patients and their families who entrust us with their care. As we continue on this journey, Prevail remains driven by our shared passion for improving health outcomes and enhancing quality of life for the rare diseases community. The PROPEL trial is a gene therapy study actively recruiting patients with PD-GBA, ages 35–80 years. To learn more about the PROPEL trial, please visit: https://bit.ly/45MwYud #ParkinsonsDisease #GeneTherapy #PDGBA #ClinicalTrials #ABCsOfPD #GoTeamFox #OutrunPD

At Prevail Therapeutics, we are honored to spotlight the incredible work of the Michael J. Fox Foundation (MJFF). Dedicated to finding a cure for Parkinson's disease, MJFF drives a dedicated research agenda focused on developing improved therapies for those living with Parkinson's today. MJFF exists to accelerate the next generation of Parkinson’s disease treatments by identifying and funding vital projects, solving field-wide challenges, and streamlining efforts of diverse teams. Their mission is to leverage core values of optimism, tenacity, collaboration, boldness, adaptability, and curiosity on behalf of the 6 million people living with Parkinson’s worldwide. Putting patients first, MJFF works tirelessly to speed breakthroughs that make a real difference in patients' lives. They serve as a critical catalyst in the patient and research communities, pushing the most promising treatments forward through innovative approaches. Join us in supporting MJFF's mission to transform the PD research field and bring hope to millions. To learn more about their impactful work, visit: https://bit.ly/3WrdtmE #ParkinsonsDisease #PDResearch #MJFF #FindACure #PatientFirst #InnovativeResearch

We are proud to spotlight the Bluefield Project to Cure FTD, a non-profit foundation committed to advancing the development of treatments for frontotemporal dementia (FTD). The Bluefield Project funds innovative research and fosters collaboration among discovery scientists and clinical neurologists to accelerate the translation of findings into potential therapies. Their contributions are significant: funding over 26 investigators whose work led to two clinical trials and filing of two patent applications. Their investigators have screened nearly 500,000 compounds, published more than 100 papers, and trained over 50 scientists in FTD research. Through partnerships with pharmaceutical and biotech companies, the Bluefield Project is driving forward the development of much-needed therapies for FTD. Learn more about the Bluefield Project and their groundbreaking work: https://bit.ly/4d9jPhk #BluefieldProj #FTD #FrontotemporalDementia #Neurodegeneration #Research #CureFTD #endFTD